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The performance characteristics of four different assays for hepatitis B virus (HBV) quantification were
assessed: the Abbott RealTime HBV IUO, the Roche Cobas AmpliPrep/Cobas TaqMan HBV test, the
Roche Cobas TaqMan HBV test with HighPure system, and the Qiagen artus HBV TM ASR. Limit of
detection (LOD), linear range, reproducibility, and agreement were determined using a serially diluted
plasma sample from a single chronically infected subject. Each assay was tested by at least three
laboratories. The LOD of the RealTime and two TaqMan assays was approximately 1.0 log10 IU/ml; for
artus HBV (which used the lowest volume of extracted DNA), it was approximately 1.5 log10 IU/ml. The
linear range spanned 1.0 to at least 7.0 log10 IU/ml for all assays. Median values were consistently lowest
for artus HBV and highest for Cobas AmpliPrep/Cobas TaqMan HBV. Assays incorporating automated
nucleic acid extraction were the most reproducible; however, the overall variability was minor since the
standard deviations for the means of all tested concentrations were <0.32 log10 IU/ml for all assays.
False-positive results were observed with all assays; the highest rates occurred with tests using manual
nucleic acid extraction. The performance characteristics of these assays suggest that they are useful for
management and therapeutic monitoring of chronic HBV infection.
Hepatitis B virus (HBV) has infected an estimated 400
million persons worldwide; cirrhosis and hepatocellular car-
cinoma, the major sequelae of chronic hepatitis B, result in
over a half million deaths annually (4). HBV viremia is a
critical risk factor for progression of chronic HBV infection
(1); accordingly, quantification of HBV DNA in blood has
become a critical tool in the assessment and management of
chronic infection. In addition to serologic tests for HBV and
measurement of serum transaminases, HBV viral load test-
ing is used to determine the phase of chronic HBV infection
(8) and is particularly useful in distinguishing active from
inactive disease in individuals with no detectable HBeAg. A
number of antiviral drugs have been introduced recently for
the treatment of chronic HBV infection, and viremia is an
important component in the decision to initiate treatment
and in monitoring therapeutic response (5, 7).
Viremia in chronic HBV infection varies from very low or
undetectable to 108 copies/ml. Effective quantitative assays
must therefore measure a wide range of viral DNA concentra-
tions. Commercially available quantitative assays utilize a variety
of different detection methods, including signal amplification
(Versant HBV bDNA; Siemens Healthcare Diagnostics), con-
ventional PCR (Amplicor HBV Monitor test; Roche Diagnos-
tics), and real-time PCR (Cobas AmpliPrep/Cobas TaqMan
HBV test [Roche Diagnostics] and RealTime HBV assay [Abbott
Molecular]). Of these methods, only real-time PCR is able to
cover the wide dynamic range required for quantification of the
virus in all stages of infection.
Reported studies of real-time assays have mainly focused on
the performance of individual tests compared to signal ampli-
fication tests rather than the comparative performance of mul-
tiple real-time PCR tests (2, 3, 6, 9). The present study assessed
the limit of detection, linear range, reproducibility, and agree-
ment among four commercially available real-time PCR HBV
viral load tests: the Abbott RealTime HBV IUO, the Roche
Cobas AmpliPrep/Cobas TaqMan HBV test, the Roche Cobas
TaqMan HBV test with HighPure system, and the Qiagen artus
HBV TM ASR. The Abbott m2000sp and Roche AmpliPrep
protocols were performed using automated extraction meth-
ods, while the extractions for the Roche HighPure and Qiagen
ASR were performed manually.
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MATERIALS AND METHODS
Quantification panels. A 65-specimen panel was created to be used by par-
ticipating laboratories to assess assay performance. The panel was created in a
centralized laboratory (the Division of AIDS Viral Quality Assurance Labora-
tory, Rush University Medical Center, Chicago, IL) by serially diluting a unit of
plasma obtained from a patient donor infected with HBV. The diluent was
human plasmapheresis plasma containing the anticoagulant sodium citrate
(SeraCare, Milford, MA) and found to be negative for HBsAg by serologic
testing; this also served as negative sample material. HBV-infected donor blood
was obtained under an institutional review board-approved protocol. The plasma
was assigned a nominal concentration of 8.58 log10 IU/ml of genotype A virus as
determined by Versant HBV DNA 3.0 (Siemens, Hoffman Estates, IL). Four
replicates each of three different dilutions (1:100, 1:1,000, and 1:10,000) were
tested to determine IU/ml.
HBV genotype was determined by direct sequencing of the sequence of the
polymerase gene (nucleotides 1 to 1615 and 2528 to 3221 of the circular genome)
by BLAST analysis and alignment with sequences in GenBank. The panel con-
sisted of 5 to 7 replicates of 10 concentrations ranging from 1.0 to 7.7 log10 IU/ml
each in a volume of 750 l (Table 1). Panel members were tested in a blinded
manner by participating laboratories.
Viral load assays. Four HBV viral load assays were evaluated, including
RealTime HBV IUO with m2000sp automated sample preparation (Abbott
Molecular, Des Plaines, IL), TaqMan48 HBV ASR with AmpliPrep automated
sample preparation (Roche Diagnostics, Indianapolis, IN), TaqMan HBV RUO
with HighPure system manual sample preparation (Roche), and artus HBV TM
ASR with QIAamp MinElute Virus Spin kit manual sample preparation
(Qiagen, Germantown, MD). The plasma extraction volume was 500 l for the
AmpliPrep TaqMan, HighPure TaqMan, and RealTime assays and 200 l for the
Qiagen artus HBV TM assay. An internal control (IC) for the RealTime and
artus HBV assays and a quantitation standard (QS) for the TaqMan assays were
processed simultaneously with the samples during the extraction. The elution
volumes from the extractions were 75 l for the two TaqMan assays, 70 l for the
RealTime assay, and 60 l for the artus HBV assay. The real-time PCR ampli-
fication mixtures for the two TaqMan assays and the RealTime assay contained
50 l of extracted sample plus 50 l of amplification master mix supplied with the
manufacturer’s reagents (total volume of 100 l) for each assay, while the artus
HBV amplification used 20 l of sample extract plus 30 l of master mix for a
total amplification volume of 50 l. Amplification and quantification were per-
formed per package insert if available; otherwise, protocols were developed in
collaboration with manufacturers’ research and development expertise.
Study design. The panels were used to determine the limit of detection, linear
range, reproducibility, and agreement for each assay. The two Roche assays and
the Qiagen assay were each performed by four different laboratories. Only three
laboratories were able to perform the Abbott assay; therefore, one laboratory
tested two complete panels so that the same number of replicates was tested for
all assays.
Statistical analysis. HBV concentrations were log10 transformed for analysis.
Results that were reported as “not extracted” in the AmpliPrep TaqMan assay or
as invalid in any assay were excluded from the analysis. For each assay, results
from all laboratories were combined when calculating means and medians. Stan-
dard deviations accounted for variation between laboratories within a given assay
platform. Medians were not generated for a given nominal concentration if fewer
than 50% of the samples produced a quantitative estimate. Means and standard
deviations were not generated for a given nominal concentration if a valid
quantitative result was not obtained for all samples tested.
RESULTS
The detection rates of the different tests are summarized in
Table 2. All tests were highly sensitive, with the RealTime,
AmpliPrep TaqMan, and High Pure TaqMan assays qualita-
tively detecting all 27 or 28 replicates of the 1.0-log10-IU/ml
sample. The artus HBV test detected 24/28 1.0-log10-IU/ml
replicates and all 28 replicates of the 1.5-log10-IU/ml sample.
Although false-positive results occurred with all of the assays,
they were seen more frequently in the assays that used manual
extraction methods (4/28 for the HighPure TaqMan test and
5/28 for the artus HBV assay, compared to 1/28 for the Real-
Time and 2/28 for the AmpliPrep TaqMan assays). False-
positive results were not confined to any one laboratory; 50%
of the false-positive results were from samples that were adja-
cent to a sample with a very high viral load (10 million
IU/ml).
The median viral load values and intraquartile ranges for the
four viral load assays are shown in Table 3. Overall, there was
good agreement in viral load values between the assays. For
samples with a nominal concentration ranging from 1.5 log10
IU/ml to 7.0 log10 IU/ml, the differences in the median viral
load values across the four assays were between 0.29 log10
IU/ml and 0.56 log10 IU/ml. The samples with nominal con-
centrations of 1.0 log10 IU/ml and 7.7 log10 IU/ml were not
analyzed because values were not available for all four assays.
The standard deviations of the mean viral load values are
shown in Table 4. In most instances, lower standard deviations
were observed at concentrations greater than 2.0 log10 IU/ml.
All assays were linear to 7.7 log10 IU/ml with the exception of
the AmpliPrep TaqMan assay, as all 7.7-log10-IU/ml values
were above the upper linear range of the assay (8.04 log10
TABLE 1. HBV panel composition
No. of
samples
Nominal concn
IU/ml Log10 IU/ml
7 0 0
7 10 1.0
7 30 1.5
7 100 2.0
7 300 2.5
5 1,000 3.0
5 10,000 4.0
5 100,000 5.0
5 1,000,000 6.0
5 10,000,000 7.0
5 50,000,000 7.7
TABLE 2. Detection rate of the HBV viral load assays
Assay
No. detected/no. of valid results at each nominal concn (log10 IU/ml)
0 1.0 1.5 2.0 2.5 3.0 4.0 5.0 6.0 7.0 7.70
RealTime HBV 1/28 28/28 28/28 28/28 28/28 20/20 20/20 20/20 20/20 20/20 20/20
AmpliPrep TaqMan HBVa 2/28 27/27 28/28 28/28 28/28 19/19 18/18 20/20 20/20 20/20 20/20
HighPure TaqMan HBVb 4/28 28/28 28/28 28/28 28/28 19/19 20/20 20/20 20/20 18/18 20/20
artus HBV TM ASR 5/28 24/28 28/28 28/28 28/28 20/20 20/20 20/20 20/20 20/20 20/20
a Four samples invalid or not extracted.
b Three samples invalid or not extracted.
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IU/ml) and were reported as such by the TaqMan instrument
(Fig. 1).
The assay bias, expressed as log10 IU/ml viral load values
minus the nominal concentration, is shown in Fig. 2. The
RealTime assay showed very consistent bias for samples
greater than or equal to 3.0 log10 IU/ml. The AmpliPrep Taq-
Man assay consistently gave the highest viral load values, and
there was variable bias throughout the linear range of the
assay. A similar pattern of bias was seen with the HighPure
TaqMan assay, although the values were lower than those seen
with the AmpliPrep TaqMan assay. The artus HBV assay
showed consistent bias for samples above 2.0 log10 IU/ml and
overall showed the lowest viral load values.
DISCUSSION
This comparison of four real-time PCR assays demonstrated
that they have very similar performance characteristics, al-
though some differences were noted. For example, the two
TaqMan and the RealTime assays had a lower limit of detec-
tion of 1.0 log10 IU/ml, compared to 1.5 log10 IU/ml for the
artus HBV assay. This minor difference is likely due to plasma
input volume differences between artus HBV (200 l) and the
other assays (500 l). In addition, a lower percentage of the
extracted DNA was added to the master mix with the artus
HBV assay compared to the other three assays (33% versus
70%). Despite this analytical difference, all assays had de-
tection limits within the necessary range for clinical decision
making.
Another difference that was observed pertained to false-
positive rates. Assays that relied on manual extraction (High-
Pure TaqMan and artus HBV) had higher false-positive rates
than did those that employed automated extraction (RealTime
and AmpliPrep TaqMan assays). The occurrence of false-pos-
itive results with automated extraction platforms is an impor-
tant observation that may reflect the performance expected in
the clinical laboratory, where samples with viral load values in
excess of 8.0 log10 IU/ml may be tested alongside samples
containing no virus. These data suggest that regardless of the
extraction method employed, careful attention to good labo-
ratory practices will be needed to avoid false-positive results
due to the extraordinarily high viral loads that occur in chronic
HBV infections.
All four assays demonstrated a broad linear range of approx-
imately 7 log10 IU/ml; we were unable to obtain a large-volume
sample with a higher viral load to better define the upper limits
of linearity of the assays. Quantification of the 7.7-log10-IU/ml
sample resulted in concentrations that exceeded the upper
limit of the AmpliPrep TaqMan assay but not those of the
other three assays. According to the AmpliPrep TaqMan pack-
age insert, it would have been acceptable to dilute these high-
concentration samples up to 1:100 in order to report out a
value up to 10.23 log10 IU/ml; however, specimen dilution was
not part of the study protocol and, therefore, it was not per-
formed. This approach is appropriate for all of the assays as
long as the dilution process is validated by the laboratory.
The reproducibility of the assays was similar to that seen
with other real-time PCR tests. For viral load values in the
middle of the linear range where the standard deviations are
0.05 to 0.10 log10 IU/ml, a change in viral load that is greater
than 3-fold would be interpreted to be a significant difference.
For viral load values less than 2.0 log10 IU/ml, where the
standard deviation is higher, 5-fold changes would be signifi-
cant. Overall, the artus HBV assay was the least precise of the
four assays evaluated; this may in part reflect the manual
extraction method.
The differences in the median viral load values obtained with
TABLE 3. Median viral load values and intraquartile ranges
Log10 nominal
concn (IU/ml)
Median (Q1, Q3)
RealTime HBV AmpliPrepTaqMan HBV HighPure TaqMan HBV artus HBV TM ASR
1.0 1.18 (1.10, 1.34) 0.85 (0.78, 1.00) —a 0.65 (0.39, 0.90)
1.5 1.57 (1.52, 1.73) 1.54 (1.40, 1.74) 1.26 (1.11, 1.33) 1.11 (0.90, 1.34)
2.0 2.02 (1.96, 2.13) 2.20 (2.11, 2.24) 1.89 (1.82, 1.95) 1.83 (1.55, 1.98)
2.5 2.44 (2.40, 2.49) 2.73 (2.67, 2.78) 2.42 (2.38, 2.45) 2.25 (2.11, 2.35)
3.0 2.89 (2.80, 2.93) 3.34 (3.23, 3.40) 3.00 (2.96, 3.03) 2.78 (2.69, 2.82)
4.0 3.85 (3.84, 3.90) 4.30 (4.24, 4.38) 4.08 (4.03, 4.11) 3.79 (3.64, 3.85)
5.0 4.87 (4.83, 4.92) 5.18 (5.12, 5.22) 4.92 (4.85, 4.95) 4.78 (4.69, 4.88)
6.0 5.91 (5.86, 5.94) 6.14 (6.10, 6.17) 5.85 (5.84, 5.87) 5.86 (5.71, 5.92)
7.0 6.93 (6.89, 6.96) 7.32 (7.26, 7.37) 6.98 (6.94, 7.02) 6.90 (6.77, 6.96)
7.7 7.66 (7.61, 7.69) —b 7.86 (7.80, 7.91) 7.52 (7.35, 7.59)
a Nineteen of 28 samples reported as “detected, 6 IU/ml.”
b All 20 samples reported as 8.04 log10 IU/ml (110,000,000 copies/ml).
TABLE 4. Standard deviations of the mean viral load values
Log10 nominal
concn (IU/ml)
RealTime
HBV
AmpliPrep
TaqMan
HBV
HighPure
TaqMan
HBV
artus HBV
TM ASR
n SD n SD n SD n SD
1.00
1.50 28 0.19 28 0.22 27 0.14 28 0.32
2.00 28 0.13 28 0.11 28 0.25 28 0.27
2.50 28 0.08 28 0.13 28 0.12 28 0.16
3.00 20 0.09 19 0.11 19 0.10 20 0.13
4.00 20 0.10 18 0.10 20 0.10 20 0.13
5.00 20 0.06 20 0.10 20 0.07 20 0.11
6.00 20 0.05 20 0.09 20 0.06 20 0.27
7.00 20 0.07 20 0.11 18 0.13 20 0.13
7.70 20 0.07 —a —b 20 0.16
a All 20 samples reported as 8.04 log10 IU/ml.
b Three samples reported as 8.04 log10 IU/ml.
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the four assays ranged from 0.29 log10 IU/ml to 0.56 log10
IU/ml. The smallest difference was seen for the 6.0-log10-IU/ml
sample, and the largest difference was seen for the 3.0-log10-
IU/ml sample. The most consistent bias (difference between
nominal concentration and observed concentration) was seen
with the artus HBV assay for values of 2.0 log10 IU/ml and
with the RealTime assay for values of 3.0 log10 IU/ml. Both
TaqMan assays showed an inconsistent bias throughout the
linear range of the assays. One limitation of this study is that
only a genotype A sample was studied, so it is not possible to
determine if any of these assays has a genotype bias.
The availability and regulatory status of the investigated
assays have changed since the conclusion of experimentation.
The artus HBV assay is available outside the United States as
a Conformite´ Europe´enne (CE)-marked product. The Real-
Time and TaqMan reagents have been approved for use by the
U.S. Food and Drug Administration (U.S. FDA) and are CE
marked. Plasma volumes identical to those used in this study
are used in the U.S. FDA-approved assays. The RealTime
assay is additionally approved for use with 200 l of plasma.
Comparative performance of the assay with this reduced vol-
ume was not investigated in this study.
Though there is reasonable agreement in viral load values
across the four assays, the intra-assay and between-assay vari-
ability are such that patients should be monitored with a single
assay. False positives were observed on all platforms, and care-
FIG. 1. Linear range of the viral load assays.
FIG. 2. Assay bias of the four real-time PCR assays for HBV quan-
tification. Bias is defined as measured viral load (log10 IU/ml) minus
the nominal concentration of the sample (log10 IU/ml).
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ful attention should be paid to avoid cross-contamination by
samples that may contain extremely high concentrations of this
virus.
In summary, all four assays are similarly sensitive and have
a broad linear range, providing clinical utility for both diag-
nostic testing and therapeutic monitoring.
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